PALB2 Test for Breast Cancer: Cancer Risk, DNA Repair, Variant Meaning, and Family Risk

A PALB2 test looks for inherited changes in the PALB2 gene that can raise the risk of breast cancer and several other cancers. PALB2 helps repair damaged DNA by working closely with BRCA1 and BRCA2. When one inherited copy contains a pathogenic or likely pathogenic variant, DNA repair can be less effective, increasing lifetime cancer susceptibility. For women, PALB2 is considered a major breast cancer predisposition gene, with lifetime risk estimates that can overlap the lower range reported for BRCA2 in some families. The meaning of a result depends on the exact laboratory classification: a pathogenic or likely pathogenic variant can change screening and family counseling, while a variant of uncertain significance should not be used to make preventive surgery or treatment decisions. PALB2 testing is usually performed on blood or saliva as part of germline genetic testing. It is different from tumor-only sequencing, and a positive result may have implications for relatives as well as the person tested.

• PALB2 is a DNA-repair gene that works in the same homologous-recombination pathway as BRCA1 and BRCA2.
• A germline pathogenic PALB2 variant substantially increases female breast cancer risk, but individual risk varies with age and family history.
• A variant of uncertain significance is not treated as a positive hereditary cancer result.
• A confirmed germline result can affect breast screening, risk-reducing discussions, and testing of relatives.
• PALB2 testing does not by itself diagnose cancer or predict exactly whether cancer will develop.

Table of Contents

• What PALB2 does in DNA repair
• Who may be offered PALB2 testing
• What positive, negative, and uncertain results mean
• How much PALB2 can increase breast cancer risk
• Screening and risk-reduction after a positive result
• PALB2 results after a breast cancer diagnosis
• Family risk, cascade testing, and next steps

What PALB2 does in DNA repair

PALB2 stands for “partner and localizer of BRCA2.” The gene makes a protein that helps position BRCA2 at sites of DNA damage and supports homologous recombination, a high-fidelity process cells use to repair double-strand DNA breaks. PALB2 also interacts functionally with BRCA1. Together, these proteins help maintain chromosome stability and prevent the accumulation of genetic damage that can contribute to cancer.

Everyone normally has two copies of PALB2, one inherited from each biological parent. A person with a germline pathogenic variant usually has one altered copy in every cell. The remaining working copy often provides enough function for normal development, but if a breast cell later loses or disables the second copy, DNA repair may become impaired. That loss can favor tumor development.

This is why PALB2 is grouped with hereditary breast cancer genes rather than with routine tumor markers such as ER, PR, or HER2. A breast cancer gene panel may analyze PALB2 together with BRCA1, BRCA2, CHEK2, ATM, and other genes selected according to the laboratory and clinical indication.

The test also differs from a tumor genomic profile. Tumor sequencing can sometimes detect a PALB2 alteration that developed only in the cancer. Germline testing asks whether the variant was inherited and is present throughout the body. If tumor-only testing identifies a potentially important PALB2 variant, confirmatory germline testing may be recommended before concluding that relatives are at risk.

Rarely, a child who inherits disease-causing PALB2 variants from both parents can develop a form of Fanconi anemia. This is a different, recessive condition from the adult hereditary cancer risk caused by carrying one pathogenic PALB2 variant. Reproductive counseling may therefore be relevant when both partners are known carriers.

Who may be offered PALB2 testing

PALB2 is commonly included on multigene hereditary cancer panels. Testing may be considered after a breast cancer diagnosis or in an unaffected person whose personal or family history suggests inherited susceptibility.

Current breast cancer germline-testing guidance has broadened access to genetic testing. ASCO and the Society of Surgical Oncology recommend BRCA1/2 testing broadly for newly diagnosed patients through age 65 and for selected older patients, while testing of additional high-penetrance genes is guided by family history and whether the result would affect personal or family risk management. PALB2 is one of the important genes considered when an expanded hereditary breast cancer panel is appropriate.

Features that may increase the reason to discuss a broader panel include:

• breast cancer at a young age;
• multiple primary breast cancers or bilateral breast cancer;
• male breast cancer in the family;
• a strong family history of breast, ovarian, pancreatic, or related cancers;
• a relative with a known PALB2 pathogenic variant;
• ancestry or family patterns associated with inherited cancer susceptibility; and
• a clinical situation in which hereditary findings could affect treatment or prevention planning.

Testing an affected relative first is often most informative when possible. If a family has several cases of breast cancer but no known familial variant, finding the responsible alteration in someone who has had cancer can make later testing of unaffected relatives more precise.

A germline sample is usually blood or saliva. The laboratory analyzes PALB2 for sequence changes and, depending on the assay, larger deletions or duplications. Pretest counseling should explain what types of results may occur and what they could mean for insurance, relatives, screening, and medical decisions.

A negative result does not always erase hereditary concern. If no family pathogenic variant has ever been identified, a negative panel may be “uninformative”: the family history can still justify enhanced screening even though the tested genes did not reveal an explanation. By contrast, if a person tests negative for a specific PALB2 variant already proven to run in the family, that is a true negative for that familial variant and can substantially change inherited-risk assessment.

What positive, negative, and uncertain results mean

Genetic laboratories classify variants using evidence about how strongly a change disrupts gene function and whether it is associated with disease. The most important categories for decision-making are pathogenic, likely pathogenic, uncertain significance, likely benign, and benign.

Result	General meaning	Typical clinical use
Pathogenic	Strong evidence the variant impairs PALB2 function and increases cancer susceptibility	Use for risk management and family testing
Likely pathogenic	High probability the variant is disease-causing	Usually managed like a pathogenic result
Variant of uncertain significance	Evidence is insufficient or conflicting	Do not use as the basis for preventive surgery or other high-stakes decisions
Likely benign or benign	Not considered a hereditary cancer-causing result	Management depends on other risk factors

A pathogenic or likely pathogenic result is often shortened to “positive,” but the exact laboratory wording matters. Genetic reports should not be interpreted only by searching the variant name online. Databases, laboratory evidence, and classifications can change over time, and some sources contain outdated or conflicting assertions.

A variant of uncertain significance, often written VUS, is not a halfway-positive result. ASCO guidance specifically states that VUS findings should not change management. Screening and treatment decisions should instead follow the person’s cancer history, family history, and other established risk factors. If a VUS is later reclassified, the testing laboratory or genetics service may issue an updated interpretation.

A negative result can mean different things. If the family’s known PALB2 pathogenic variant was specifically tested and not found, the person generally did not inherit that familial variant. If no familial cause is known, however, a negative result does not prove the family’s cancers were nonhereditary. Other genes, variants not detected by the assay, polygenic factors, and shared environmental influences can still contribute.

Because germline PALB2 testing answers a hereditary-risk question, it should not be confused with the BRCA1/BRCA2 test. The genes overlap in pathway and management principles, but a PALB2 result is its own result with its own evidence and risk estimates.

How much PALB2 can increase breast cancer risk

PALB2 is considered a high-penetrance or major breast cancer susceptibility gene. The exact lifetime risk is not a single fixed percentage because risk changes with age, family history, birth cohort, reproductive factors, and other genetic influences.

An international analysis of 524 families with germline PALB2 pathogenic variants estimated female breast cancer risk at about 53% by age 80, with a 95% confidence interval of roughly 44% to 63%. NCI’s current PALB2 summary reports a similar estimate of about 52.8% by age 80 from this study. Earlier family data showed that risk can be higher when several close relatives developed early breast cancer.

Those figures describe groups, not destiny for one person. A 30-year-old carrier does not have a 53% chance of developing breast cancer in the next few years, and an older carrier who has remained cancer-free has already passed through part of the lifetime-risk period. Genetics professionals may use individualized models to account for age and family history rather than relying on one lifetime number.

PALB2 also affects risk beyond a first female breast cancer. Prospective data suggest an increased risk of cancer in the opposite breast for some carriers, particularly premenopausal women whose first tumor was ER-negative. The magnitude varies by subgroup, so a PALB2 result does not automatically mean bilateral mastectomy is medically required.

Other cancers are associated with PALB2 as well. Large family studies support increased pancreatic cancer risk and a smaller increase in ovarian cancer risk. Male breast cancer risk is also elevated, although the absolute risk remains much lower than female breast cancer risk. The NCI notes that pancreatic-screening recommendations can differ among professional groups, especially when there is no family history of pancreatic cancer.

Risk estimates continue to evolve as more carriers are followed prospectively. That is one reason a genetics visit can remain useful years after the original test: screening ages, surgical recommendations, and cancer-risk estimates may be updated as evidence changes.

Screening and risk-reduction after a positive result

A confirmed germline pathogenic or likely pathogenic PALB2 variant usually leads to enhanced breast surveillance. Current NCI guidance summarizing major professional recommendations describes annual mammography and contrast-enhanced breast MRI beginning around age 30 for women with PALB2 pathogenic variants. The exact start age and sequence can be individualized for family history, previous cancer, breast density, pregnancy, and local guidelines.

MRI and mammography are complementary. MRI is more sensitive for many high-risk women, while mammography can detect some calcifications that MRI may not show as well. Screening does not prevent cancer from developing; its purpose is to find cancer earlier if it occurs.

Risk-reducing bilateral mastectomy can be considered, but it is not an automatic requirement for every PALB2 carrier. The decision may reflect estimated lifetime risk, age, prior breast cancer, breast imaging experience, family history, other medical conditions, body image, reconstruction preferences, and how a person weighs surveillance against surgery. ACMG guidance recommends using personalized risk estimates for this discussion.

For a person who has already had breast cancer, surveillance of the remaining breast tissue may include MRI, particularly when contralateral risk is elevated. Whether to remove the opposite healthy breast is a separate preventive decision from surgery needed to treat the existing cancer.

Ovarian and pancreatic management is more individualized. PALB2-associated ovarian risk appears substantially lower than the risks associated with BRCA1 and BRCA2. Current recommendations therefore consider age, family history, menopausal consequences, and evolving evidence when discussing risk-reducing salpingo-oophorectomy. Pancreatic surveillance, when recommended, generally uses specialized MRI/MRCP and/or endoscopic ultrasound programs rather than routine abdominal screening.

The practical goal is a personalized surveillance plan rather than a list of procedures triggered by the gene name alone. Genetics and high-risk breast specialists can translate the result into ages, intervals, and prevention options appropriate to the individual.

PALB2 results after a breast cancer diagnosis

For someone who already has breast cancer, a PALB2 result can matter in two different ways: it can affect future cancer-risk management, and it may influence treatment discussions because PALB2-deficient tumors share homologous-recombination biology with BRCA-associated cancers.

The standard treatment plan still depends first on stage and tumor biomarkers. ER, PR, HER2, grade, lymph nodes, and other pathologic features determine the major treatment pathway. PALB2 does not replace those tests. A person with PALB2-associated breast cancer can have hormone receptor-positive, HER2-positive, or triple-negative disease, although ER-negative disease is seen relatively often in PALB2 carriers.

Research has shown sensitivity of some PALB2-associated cancers to DNA-damaging approaches and PARP inhibition, but approved indications can be narrower than the underlying biology. In breast cancer, U.S. PARP-inhibitor approvals have historically been tied specifically to germline BRCA1/2 in defined settings. A PALB2 result therefore should not be assumed to create the same drug eligibility automatically. Clinical trials and guidelines may provide options as evidence evolves.

A triple-negative breast cancer biomarker profile may prompt hereditary testing because inherited DNA-repair variants can be particularly relevant in this subtype, but PALB2 testing remains a germline assessment rather than a marker of triple-negative status itself.

The result can also affect surgical conversations. Someone with a newly diagnosed unilateral cancer may discuss the risk of a future cancer in the opposite breast and whether enhanced surveillance or bilateral surgery fits their values. Survival benefit from removing the healthy breast is not guaranteed, and the decision should be separated from the need to achieve good local control of the diagnosed tumor.

Treatment implications are one reason it is useful to know whether a PALB2 finding came from germline testing or tumor-only sequencing. The two can overlap biologically, but only a confirmed germline result establishes inherited risk for relatives.

Family risk, cascade testing, and next steps

A person with a germline PALB2 pathogenic variant has a 50% chance of passing that variant to each biological child. Full siblings generally have a 50% chance of carrying the same variant if one parent is a carrier, and other relatives may also be at risk depending on which side of the family the variant came from.

“Cascade testing” means offering targeted testing for the known familial variant to adult relatives. This is usually simpler and more informative than ordering a broad panel for every relative. A relative who tests positive can enter appropriate surveillance; a relative who tests negative for the known familial variant can often avoid PALB2-specific screening, although ordinary risk factors still matter.

Testing minors is generally not useful for an adult-onset PALB2 cancer predisposition because recommended breast surveillance begins in adulthood. Families can discuss the appropriate timing with a genetics professional, particularly when reproductive questions or unusual childhood conditions are present.

After a positive result, useful questions include:

1. Is my result classified as pathogenic or likely pathogenic, or is it a VUS?
2. Was this definitely a germline test, or does the finding need confirmation from blood or saliva?
3. What is my age-specific breast cancer risk rather than only my lifetime estimate?
4. When should MRI and mammography begin or continue?
5. Should I consider risk-reducing mastectomy, and what benefit would it provide for me?
6. Does my family history change ovarian or pancreatic screening recommendations?
7. Could this result affect treatment of a current breast cancer or eligibility for a clinical trial?
8. Which relatives should be offered targeted testing?
9. How will I be contacted if the laboratory changes the variant classification or recommendations evolve?

A PALB2 result is most useful when the exact variant, family history, and personal medical history are considered together. The gene identifies an inherited susceptibility; it does not determine a person’s future with certainty. Appropriate surveillance, prevention choices, and family testing can turn that information into practical risk management.

References

• PALB2: Cancer Risks and Management (PDQ®)–Health Professional Version 2025 (NCI)
• Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline 2024 (Guideline)
• Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG) 2021 (Guideline)
• UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2 2023 (Consensus)
• Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2 2023
• Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families 2020

Disclaimer

This article is for general education and does not replace individualized genetic counseling or medical advice. Cancer risks and screening recommendations for PALB2 carriers vary with age, family history, previous cancer, sex, and changing professional guidelines. A variant of uncertain significance should not be used as the basis for preventive surgery or treatment changes without expert interpretation.